Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted Pathway Inhibition in Pancreatic Cancer
NCT04005690Phase 1Recruiting
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Aug 2019
- Primary completion
- Jun 2027
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of olaparib, cobimetinib, onvansertib, azenosertib, saruparib and 1 more in pancreatic ductal adenocarcinoma (PDAC) (6 arms), sponsored by OHSU Knight Cancer Institute. Primary endpoint: Proportion of participants with a measurable change in post-treatment tumor biology from baseline at 10 days. Started Aug 2019; status: recruiting.
02
Drugs
olaparibcobimetinibonvansertibazenosertibsaruparib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04005690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04005690.